AIM ImmunoTech Inc. Announces Completion of Rights Offering and Key Corporate Updates

Washington, D.C. – March 6, 2026 – AIM ImmunoTech Inc. (“AIM” or the “Company”), a biotechnology firm listed on the NYSE American under the ticker AIM, has filed a Form 8-K with the Securities and Exchange Commission (SEC) to report several significant corporate developments that may have an impact on its share value.

Key Highlights of the Report

• Completion of Rights Offering: AIM ImmunoTech has completed a previously announced rights offering, allowing shareholders as of the February 10, 2026 record date to subscribe for new units. Each unit included both shares of common stock and Class G common stock purchase warrants.
• Amendments to Corporate Structure: The Company filed a Certificate of Designation for Series G Preferred Stock, with the full text available as Exhibit 3.1 to the 8-K. This has resulted in a material modification to the rights of security holders.
• Dealer-Manager Engagement: The rights offering was managed by Maxim Group LLC, as detailed in the Dealer-Manager Agreement (Exhibit 1.1). Maxim provided advisory services on the structure, pricing, timing, and terms of the offering.
• Listing Status: AIM’s common stock remains registered and actively traded on NYSE American.
• Comprehensive Covenants and Representations: The Company has provided extensive representations and warranties regarding its financial condition, legal compliance, corporate governance, and the validity of the newly issued securities. These include affirmations regarding internal controls, Sarbanes-Oxley Act compliance, intellectual property, and material contracts.

Details on the Rights Offering

• Each shareholder of record at the close of business on February 10, 2026, received one right per share of common stock or participating security held.
• Each right entitled holders to purchase one unit at the subscription price, consisting of new shares and Class G common stock purchase warrants.
• No fractional securities were issued; rights could only be exercised for whole units.
• The offering was made pursuant to an effective registration statement on Form S-1 (Registration No. 333-292085).
• Broadridge Corporate Issuer Solutions, LLC acted as the primary Information Agent, and all investor communications regarding the offering were coordinated accordingly.

Significant Corporate Amendments

• The Certificate of Designation for Series G Preferred Stock establishes new rights, preferences, and privileges for this class of shares, which may impact future voting and dividend policies.
• The rights offering and related transactions were structured to comply with all applicable federal and state securities laws, and the Company has made representations that no preemptive or similar rights were violated in the issuance of any shares.
• The Company has covenanted to use the proceeds from the rights offering as described in its prospectus, with a focus on advancing its business and research operations.

Shareholder Considerations and Potential Price Sensitivities

• Potential Dilution: The rights offering increases the number of shares outstanding and introduces new preferred stock and warrants, which may dilute existing shareholders’ positions.
• Warrant Exercise and Further Dilution: The Class G common stock purchase warrants, once exercised, will increase the number of shares in circulation, which may further affect share price.
• Lock-Up Period: The Company has committed not to issue additional common stock or equivalents for up to 90 days post-closing (depending on gross proceeds), except for exempt issuances, which can stabilize the share price temporarily.
• Listing Assurance: The Company has applied for and is using its best efforts to ensure all newly issued shares from the rights offering and warrant exercises will be listed on NYSE American, ensuring liquidity for investors.
• Financial and Legal Safeguards: The Company provided extensive disclosures and undertook legal obligations to ensure compliance with SEC, NYSE, and FINRA regulations. No stop orders or material adverse changes have been reported since the last balance sheet date.
• No Stabilization or Manipulation: The Company explicitly covenants not to engage in any price stabilization or manipulation activities related to its securities.
• Use of Proceeds: Proceeds from the rights offering will be applied as described in the prospectus, which may include continued research, development, and working capital needs.
• Ongoing Reporting and Transparency: The Company has covenanted to provide ongoing reports, financial statements, and updates to shareholders and the Dealer-Manager throughout and after the offering process.

Conclusion

This rights offering represents a significant corporate action by AIM ImmunoTech Inc., with potential implications for share dilution, capital structure, and future business development. Shareholders are advised to consider the potential dilutive effects and to review the full prospectus and accompanying exhibits for additional details.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should review all official SEC filings and consult their financial advisors before making any investment decisions.

View AIM ImmunoTech Inc. Historical chart here